GlassScriptPhysician profile
David Matthew Graff
NPI 1144635038
$39,252.82
in general payments reported to CMS, 2019-2025
30 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,658 · 2020: $299 · 2021: $5,499 · 2022: $617 · 2023: $480 · 2024: $22K · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $22K · Food and Beverage: $404 · Travel and Lodging: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $22,400.00 |
| Food and Beverage | $403.70 |
| Travel and Lodging | $376.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $22,400.00 | 2024 | |
| Osteomed LLC | $5,227.23 | 2019-2021 | |
| Anika Therapeutics, INC. | $3,995.26 | 2021-2023 | Drawtight, Tactoset, X-Twist |
| Stryker Corporation | $2,904.95 | 2019-2020 | |
| Active Medical, LLC | $1,275.00 | 2019-2021 | |
| Paragon 28, INC. | $1,022.93 | 2019 | |
| Abbott Laboratories | $515.50 | 2021-2022 | |
| Arthrosurface Incorporated | $428.63 | 2019-2020 | |
| Horizon Therapeutics Plc | $182.86 | 2020-2021 | |
| Bone Support INC. | $144.90 | 2025 | Ceramentbone Void Filler, Cerament G |
| Sanara Medtech INC. | $139.11 | 2021 | |
| Bioventus LLC | $136.76 | 2019-2021 | |
| Alfasigma USA, INC. | $124.83 | 2020 | |
| Kerecis Limited | $110.52 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organogenesis INC. | $96.70 | 2019-2023 | Puraply |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imbed Biosciences INC. | $80.91 | 2022 | |
| Ossio INC | $64.26 | 2022-2023 | |
| Zyla Life Sciences, INC. | $61.29 | 2019-2020 | |
| Abbvie INC. | $58.12 | 2021-2022 | |
| Dynasplint Systems INC. | $56.00 | 2021 | |
| Acell, INC. | $32.89 | 2020 | |
| Triad Life Sciences INC. | $32.82 | 2021 | |
| Solventum Corporation | $28.22 | 2024 | Activ.A.C. |
| Novastep INC. | $28.14 | 2022 | |
| Allergan, INC. | $27.28 | 2020 | |
| Treace Medical Concepts, INC. | $17.15 | 2022 | |
| Tactile Systems Technology INC | $16.75 | 2024 | Flexitouch Plus, Entre Plus |
| Celularity INC. | $16.00 | 2019 | |
| Smith+Nephew, INC. | $14.57 | 2020 | |
| Merz North America, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Graff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.